The estimated Net Worth of Michael D. Mc Neil is at least $1.03 Millón dollars as of 12 April 2023. Mr Neil owns over 1,000 units of Sanara MedTech stock worth over $771,568 and over the last 5 years he sold SMTI stock worth over $0. In addition, he makes $256,212 as CFO & Corp. Sec. at Sanara MedTech.
Mr has made over 1 trades of the Sanara MedTech stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of SMTI stock worth $6,000 on 12 April 2023.
The largest trade he's ever made was exercising 1,000 units of Sanara MedTech stock on 12 April 2023 worth over $6,000. On average, Mr trades about 71 units every 0 days since 2020. As of 12 April 2023 he still owns at least 23,025 units of Sanara MedTech stock.
You can see the complete history of Mr Neil stock trades at the bottom of the page.
Michael D. McNeil is the CFO & Corp. Sec. at Sanara MedTech.
As the CFO & Corp. Sec. of Sanara MedTech, the total compensation of Mr McNeil at Sanara MedTech is $256,212. There are 2 executives at Sanara MedTech getting paid more, with Zachary B. Fleming having the highest compensation of $345,410.
Mr McNeil is 55, he's been the CFO & Corp. Sec. of Sanara MedTech since . There are 5 older and 3 younger executives at Sanara MedTech. The oldest executive at Sanara MedTech Inc. is Cathy Bradshaw, 67, who is the Pres of Wound Care Innovations LLC.
Michael's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $134,660 worth of Sanara MedTech stock and bought 963,856 units worth $8,000,005 . The most active insiders traders include Ronald T Nixon, James W Stuckert y Zachary B. Fleming. On average, Sanara MedTech executives and independent directors trade stock every 148 days with the average trade being worth of $6,486,564. The most recent stock trade was executed by Zachary B. Fleming on 26 October 2021, trading 1,000 units of SMTI stock currently worth $34,040.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: